Analyzing R&D Budgets: Bristol-Myers Squibb Company vs CRISPR Therapeutics AG

A Decade of Innovation: R&D Spending in Biopharma

In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Bristol-Myers Squibb Company and CRISPR Therapeutics AG have demonstrated contrasting R&D investment strategies.

Bristol-Myers Squibb, a stalwart in the industry, has consistently invested heavily in R&D, with expenditures peaking at approximately $11 billion in 2020. This represents a remarkable 145% increase from 2014, underscoring their commitment to pioneering new treatments.

In contrast, CRISPR Therapeutics AG, a leader in gene-editing technology, has shown a more modest yet significant growth trajectory. Their R&D spending surged from a mere $1.5 million in 2014 to nearly $462 million in 2022, marking an exponential increase of over 30,000%.

These figures highlight the diverse approaches to innovation within the biopharma sector, reflecting both the scale and agility required to drive medical breakthroughs.